Anaplastic large cell lymphoma
MONDO:0020325Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell non-Hodgkin lymphoma, belonging to the group of CD30-positive lymphoproliferative disorders, which affects lymph nodes and extranodal sites. It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL.
Also known as: ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, anaplastic large cell lymphoma
2024 clinical trials for this condition and its sub-types, 66 tagged with Anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Anaplastic large cell lymphoma
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase 2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental combo therapy shows promise for Tough-to-Treat lymphomas
Disease control CompletedThis phase 1/2 trial tested a new treatment for people with CD30-positive Hodgkin or non-Hodgkin lymphomas that returned or didn't respond to prior therapy. The treatment combines AFM13, an antibody that targets cancer cells, with natural killer (NK) cells from donated umbilical …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Targeted drug shows promise for rare blood cancer in completed trial
Disease control CompletedThis completed Phase 4 trial tested the drug brentuximab vedotin in 50 adults with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL), a rare blood cancer. Participants had already received at least one round of chemotherapy. The study measured how many patien…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 19:04 UTC
-
Your Child's genes: a new clue in fighting a rare cancer?
Knowledge-focused CompletedThis study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the di…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Lymphoma drug safety under the microscope in 1,000-Patient study
Knowledge-focused CompletedThis study follows 1,000 people with CD30-positive lymphoma who are already receiving or about to receive brentuximab vedotin as part of their normal care. Researchers will track side effects and how the drug is used in everyday practice, without giving any new treatment. The goa…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC